Skip to main content
All Posts By

adminpcb

Moirai Biodesign developes a diagnostic kit for the detection of sepsis in three hours

Moirai Biodesign, a biotech start-up based in the Barcelona Science Park, has developed a prototype ‘kit’ based on biosensors that analyzes a blood sample and identifiesthe most important sepsis-causing pathogens and their associated antibiotic resistances, at the point of care and directly from the patient’s blood, in just three hours, a process that usually requires up to 5 days of analysis in the laboratory. The company has just received a €75,000 grant through the Startup Capital financing line from ACCIÓ to  to set about the activities derived from the execution of the initial business plan. Its objective is to market this device in hospitals, once the validation phase is completed.The kit will allow identification 

Read More

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.

 

 

Read More

Ernest Giralt, first IRB Barcelona Emeritus Professor

Ernest Giralt Lledó is retiring after 15 years at the Institute for Research in Biomedicine (IRB Barcelona), where he has played a key institutional and scientific role. Dr Giralt, today an international reference for science of excellence, will continue to be linked to Institute as an Emeritus Professor. This appointment will allow him to share his guidance and expertise with the current community of scientists.

 

Read More

Scott Boyer joins Chemotargets as new CEO

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. With the new incorporation, the company, based in the Barcelona Science Park, consolidates its transition from a software business to an AI-driven biotech company.

 

Read More

The Barcelona Science Park is committed to becoming Catalonia’s MedTech company hub

The Barcelona Science Park (PCB), a Spain’s leading scientific, technological and business innovation hub in the life sciences field, aims to embark on a new phase of growth, offering more than 1,200 square metres of office space, particularly to companies in the MedTech sector. To promote this ecosystem, it has signed an alliance with GENESIS Biomed. This consultancy firm, based in PCB, has raised more than 60 million euros for its clients since it was founded in May 2017 by Josep Lluis Falcó.

 

Read More

A pioneering study conducted by Eugin reveals that women with Covid-19 produce virus-free eggs

A study carried out by a team of researchers from Eugin’s Basic Research Laboratory, headquartered in the Barcelona Science Park, published in the  journal Human Reproduction, has, for the first time, analysed the eggs of women diagnosed with Covid-19 detecting no viral material within them. The findings, globally considered ground-breaking and pioneering in the field of assisted reproduction, supports the notion that there would be no vertical transmission of the infection from mother to child via their eggs.

 

Read More

Oncoheroes receives from FDA the Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma

Oncoheroes Bioscience –a Boston based biotech with the European subsidiary at the Barcelona Science Park– focused on advancing new therapies for childhood cancer, is pleased to announce that the United States Food and Drug Administration (FDA) has granted the designation of rare pediatric disease to volasertib, an investigational treatment for rhabdomyosarcoma.

 

Read More